Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
Information source: Pfizer
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder; Vasomotor Symptoms
Intervention: desvenlafaxine succinate (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021
Summary
This is a non-interventional study to review safety data on administration of desvenlafaxine
succinate among Filipino patients with MDD and VMS per usual clinical practice within the
first three years post commercial distribution.
Clinical Details
Official title: An Open Label, Non-Interventional Study of the Safety of Desvenlafaxine Succinate (Pristiq) in the Treatment of Major Depressive Disorder (MDD) and Vasomotor Symptoms (VMS) Associated With Menopause in Filipino Adult Patients: a Post Marketing Surveillance Study
Study design: Time Perspective: Prospective
Primary outcome: Safety assessments as measured by evaluating any reported adverse events, scheduled physical examinations and vital signs assessments.
Detailed description:
post marketing surveillance none
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to
menopause prescribed with desvenlafaxine succinate
Exclusion Criteria:
Hypersensitivity to desvenlafaxine succinate
Locations and Contacts
Pfizer CT.gov Call Center, Phone: 1-800-718-1021
Private Clinic, Manila, Philippines; Recruiting
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: March 2012
Last updated: January 29, 2013
|
